Previous 10 | Next 10 |
ABVC Biopharma ( NASDAQ: ABVC ) said on Friday that a Phase II Part 2 study testing its ADHD drug, ABV-1505, currently being conducted at five medical centers in Taiwan, had enrolled 30 subjects and eighteen of the enrolled participants had completed t...
Fremont, CA - ( NewMediaWire ) - September 22, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced enrollment progress in the Phase II Part 2 clinical study of t...
Fremont, CA - ( NewMediaWire ) - September 13, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a letter to shareholders. Dear Shareholders, I would like...
New Australia Site Confirmed to Participate in the Study Fremont, CA - ( NewMediaWire ) - September 09, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou...
New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and op...
Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...
ABVC BioPharma ( NASDAQ: ABVC ) on Thursday said it had got an approval from the ethics committee of a Thai hospital to conduct a phase 2 clinical study protocol for its vitreous substitute Vitargus. Shares of the micro-cap clinical-stage biopharmaceutical company opened 5.6...
ABVC BioPharma press release ( NASDAQ: ABVC ): Q2 GAAP EPS of -$0.06 beats by $0.07 . Revenue of $0.31M (+933.3% Y/Y) beats by $0.3M . For further details see: ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results f...
-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematol...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
FREMONT, CA - ( NewMediaWire ) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...
FREMONT, CA - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...